BD Marks 1,000th BD Rhapsody System, Driving Scientific Breakthroughs via Single-Cell Multiomics

FRANKLIN LAKES, N.J., Sept. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the placement of the 1,000th BD Rhapsody™ System, a flagship instrument for single-cell multiomics analysis, at Addenbrooke's Hospital of the University of Cambridge, United Kingdom. Together with its comprehensive menu of assays for DNA, RNA, and protein analysis, the instrument enables scientists to capture deeper insights from hundreds of thousands of single cells at a time.

Read more at prnewswire.com